DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics ...
DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the "Company” or "Iterum” or "we”), a company focused on delivering next generation oral and IV ...
Iterum Therapeutics plc announced the publication of results from its Phase 3 clinical trial, REASSURE, in NEJM Evidence, which evaluated the efficacy of oral sulopenem compared to Augmentin® in ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
The world urgently needs new antibiotics, yet the market routinely punishes companies that take on the long, risky and ...
Iterum Therapeutics plc announced that it has partnered with EVERSANA Life Science Services to commercialize its approved product, ORLYNVAHTM, the first oral penem antibiotic in the U.S., aiming for a ...
Industry Veteran To Lead Commercialization of Potential New Oral and IV Antibiotic DUBLIN and CHICAGO, Feb. 20, 2018 /PRNewswire/ -- Iterum Therapeutics Limited, a clinical-stage pharmaceutical ...
DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results